1383735-65-6

Basic information

• Product Name: Ethanone, 1-(6-broMo-1H-pyrazolo[4,3-b]pyridin-1-yl)-
• Synonyms: Ethanone, 1-(6-broMo-1H-pyrazolo[4,3-b]pyridin-1-yl)-;1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)ethanone
• CAS NO: 1383735-65-6
• Molecular Formula: C₈H₆BrN₃O
• Molecular Weight: 240.05674
• Mol File: 1383735-65-6.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-(6-broMo-1H-pyrazolo[4,3-b]pyridin-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(6-broMo-1H-pyrazolo[4,3-b]pyridin-1-yl)-(1383735-65-6)
• EPA Substance Registry System: Ethanone, 1-(6-broMo-1H-pyrazolo[4,3-b]pyridin-1-yl)-(1383735-65-6)

Safety Data

• Hazardous Substances Data: 1383735-65-6(Hazardous Substances Data)

Usage

General Description

Ethanone, 1-(6-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)- is a chemical compound that contains a pyrazolo[4,3-b]pyridin-1-yl moiety attached to a ketone functional group. It is commonly used in pharmaceutical research and drug development as a building block for the synthesis of various biologically active compounds. The bromo-substituted pyrazolo[4,3-b]pyridine ring in the molecule makes it a valuable intermediate for the preparation of heterocyclic compounds with potential medicinal properties. The compound's structural features and reactivity make it a useful tool for the development of new therapeutic agents with applications in the treatment of various diseases.

Upstream product

• 911434-04-3 2-(5-bromo-3-nitro-pyridin-2-yl)-malonic acid diethyl ester 
• 911434-05-4 5-bromo-2-methyl-3-nitropyridine 
• 914358-73-9 5-bromo-2-methylpyridin-3-ylamine 
• 1301214-71-0 N-(5-bromo-2-methyl-pyridin-3-yl)-acetamide 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 594-70-7 2-Methyl-2-nitropropane 
• 110-46-3 isopentyl nitrite 

Downstream Products

• 1383735-30-5 ethyl 1H-pyrazolo[4,3-b]pyridine-6-carboxylate 
• 1383735-31-6 C₁₅H₁₂FN₃O₂ 
• 1383735-64-5 C₁₅H₁₆FN₃O₂ 
• 1383735-67-8 C₁₃H₁₀FN₃ 
• 1383735-34-9 C₁₆H₁₅ClFN₃O₃ 
• 1383733-69-4 1-(4-fluorophenyl)-4-[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butylcarbamoyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-6-carboxylic acid ethyl ester 
• 1383733-70-7 1-(4-fluorophenyl)-4-[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butylcarbamoyl]-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine-6-carboxylic acid 
• 1383733-71-8 1-(4-fluorophenyl)-l,5,6,7-tetrahydro-pyrazolo[4,3-b]pyridine-4,6-dicarboxylic acid 4-{[(S)-1-(2-methanesulfonyl-pyridin-4-yl)-butyl]-amide} 6-methylamide 

Relevant articles and documents

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

FMS-like tyrosine kinase-3 (FLT3) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been proven to play a significant role in tumor therapy. Herein, based on the previously reported JAK2/FLT3 inhibitor 18e, we described the synthesis, structure–activity relationship and biological evaluation of a series of unique 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives that inhibited FLT3 and CDK4 kinases. The optimized compound 23k exhibited low nanomolar range activities with IC50 values of 11 and 7 nM for FLT3 and CDK4, respectively. In the MV4-11 xenograft tumor model, the tumor growth inhibition rate of 23k dosed at 200 mg/kg was 67%, suggesting that 23k possessed an antitumor therapeutic effect.

PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer,or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.